In patients with type 2 diabetes, treatment with semaglutide 1 mg resulted in reductions in glucose in terms of absolute change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose, and 30 mg/dL (22%) for mean 24-hour glucose concentration
If you think it may be an emergency, call your local emergency number immediately
15 Moreover, GLP-1 RAs in diabetic patients might yield benefits beyond glycemic control, as their use decreases the risk of dementia and anxiety associated with diabetes
However, patients use the following methods for microdosing semaglutide: 1-Click Counting with pre-filled pens Semaglutide pre-filled pens are manufactured for delivering fixed doses such as 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2 mg, and 2.4 mg